Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study

被引：1

作者：

Zhang, P. ^{[1
]}

Gong, J. ^{[2
]}

Guo, H. ^{[3
]}

Han, W. ^{[4
]}

Cao, B. ^{[5
]}

Zhang, J. ^{[6
]}

Niu, Z. ^{[7
]}

Cheng, Y. ^{[8
]}

He, C. ^{[9
]}

Fan, J. ^{[10
]}

Peng, P. ^{[11
]}

Sun, C. ^{[12
]}

Wang, H. ^{[12
]}

Yu, Y. ^{[12
]}

Zhu, Y. ^{[12
]}

Wu, Y. ^{[12
]}

Li, Q. ^{[12
]}

Huang, P. ^{[12
]}

Wu, F. ^{[11
]}

Shen, L. ^{[13
]}

机构：

[1] Peking Univ, GI Dept, Beijing Canc Hosp, Canc Hosp, Beijing, Peoples R China

[2] Peking Univ Canc Hosp & Inst, Gastrointestinal Oncol, Beijing, Peoples R China

[3] Nanjing Univ, Affiliated Hosp, Nanjing Drum Tower Hosp, Sch Med,Urol, Nanjing, Peoples R China

[4] Hunan Canc Hosp, Urol, Changsha, Peoples R China

[5] Peking Univ Third Hosp, Dept Oncol, Beijing, Peoples R China

[6] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China

[7] Shandong Univ, Dept Gastroenterol, Shandong Canc Hosp, Jinan, Peoples R China

[8] Jilin Canc Hosp, Thorac Oncol Dept, Changchun, Jilin, Peoples R China

[9] Henan Canc Hosp, Urol, Zhengzhou, Peoples R China

[10] TransThera Sci US Inc, Clin Div, Gaithersburg, MD USA

[11] TransThera Sci Nanjing Inc, Nanjing, Peoples R China

[12] TransThera Sci Nanjing Inc, Clin Dept, Nanjing, Peoples R China

[13] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1856

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

670P

引用

页码：S471 / S471

页数：1